Bioventus Inc.
BVS
$8.97
-$0.18-1.97%
NASDAQ
| 12/31/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 157.90M | 138.65M | 147.66M | 123.88M | 153.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 157.90M | 138.65M | 147.66M | 123.88M | 153.64M |
| Cost of Revenue | 49.12M | 44.42M | 45.57M | 40.82M | 50.99M |
| Gross Profit | 108.78M | 94.23M | 102.09M | 83.06M | 102.66M |
| SG&A Expenses | 82.76M | 78.64M | 79.10M | 73.48M | 86.79M |
| Depreciation & Amortization | 1.30M | 1.40M | 1.44M | 1.59M | 1.77M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 136.18M | 127.39M | 129.28M | 118.90M | 142.82M |
| Operating Income | 21.72M | 11.27M | 18.38M | 4.97M | 10.83M |
| Income Before Tax | 14.14M | 4.67M | 10.31M | -3.42M | -53.00K |
| Income Tax Expenses | -3.18M | 664.00K | 1.04M | -95.00K | 550.00K |
| Earnings from Continuing Operations | 17.32M | 4.01M | 9.27M | -3.32M | -603.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.56M | -851.00K | -1.81M | 685.00K | 215.00K |
| Net Income | 14.76M | 3.16M | 7.46M | -2.64M | -388.00K |
| EBIT | 21.72M | 11.27M | 18.38M | 4.97M | 10.83M |
| EBITDA | 27.05M | 22.67M | 30.43M | 16.84M | 15.61M |
| EPS Basic | 0.22 | 0.05 | 0.11 | -0.04 | -0.01 |
| Normalized Basic EPS | 0.11 | 0.03 | 0.07 | -0.02 | 0.03 |
| EPS Diluted | 0.21 | 0.05 | 0.11 | -0.04 | -0.01 |
| Normalized Diluted EPS | 0.11 | 0.03 | 0.07 | -0.02 | 0.03 |
| Average Basic Shares Outstanding | 67.02M | 66.92M | 66.50M | 66.01M | 65.45M |
| Average Diluted Shares Outstanding | 69.26M | 68.84M | 68.54M | 66.01M | 65.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |